뒤로
Shanghai Henlius Biotech Inc(SGBCF) 가격
SGBCF 주가 차트
SGBCF 재무
Shanghai Henlius Biotech Inc
$0
0%
$0
오늘 기준:Feb 17, 10:41:43 GMT-5
수입
자산 및 부채 명세서
현금 흐름
연간
분기별
SGBCF 소득
미화 수백만 달러. 회계 연도는 2월부터 1월까지입니다.
Follow-Up Questions
Shanghai Henlius Biotech Inc의 주요 재무제표는 무엇인가요?
SGBCF의 주요 재무 비율은 무엇인가요?
Shanghai Henlius Biotech Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Shanghai Henlius Biotech Inc은 수익성이 있나요?
Shanghai Henlius Biotech Inc에 부채가 있나요?
Shanghai Henlius Biotech Inc의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
--
시가
--
일일 범위
-
52주 범위
-
거래량
--
평균 거래량
--
EPS(TTM)
--
배당수익률
--
시가총액
--
SGBCF란 무엇인가요?
Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. The company is headquartered in Shanghai, Shanghai and currently employs 3,537 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The firm mainly operates its businesses in the domestic and overseas markets.